Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)
Toshikazu Moriwaki(University of Tsukuba Hospital), Ichinosuke Hyodo(Shikoku Cancer Center), Shigemasa Yoshida(National Hospital Organization Mito Medical Center), Atsuo Takashima(National Cancer Center Hospital East), Mitsuharu Ozeki(Ibaraki Prefectural Central Hospital), Kentaro Yamazaki(Shizuoka Cancer Center), Hideaki Bando(Aichi Cancer Center), Satoshi Kato(University of Yamanashi Hospital), Narikazu Boku(Tokyo Medical University), Taroh Satoh(Osaka University Hospital), Yasuhiro Miyake(High Energy Accelerator Research Organization), Eishi Baba(Kyushu University), Mutsumi Fukunaga(Sakai Municipal Hospital), Kenji Katsumata(Tokyo Medical University), Taito Esaki(National Hospital Organization Kyushu Cancer Center), Keishi Yamashita(Saitama Medical University)
Cited by 19
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k